Skip to Content

Notice

Manufacturer of Controlled Substances Registration: Johnson Matthey Pharmaceutical Materials, Inc.

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of registration.

SUMMARY:

Johnson Matthey Pharmaceutical Materials, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Johnson Matthey Pharmaceutical Materials, Inc. registration as a manufacturer of those controlled substances.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

By notice dated April 14, 2015, and published in the Federal Register on April 22, 2015, 80 FR 22559, Johnson Matthey Pharmaceutical Materials, Inc., 25 Patton Road, Devens, Massachusetts 01434 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Pharmaceutical Materials, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances:

Controlled substanceSchedule
Amphetamine (1100)II
Methylphenidate (1724)II
Nabilone (7379)II
Hydrocodone (9193)II
Alfentanil (9737)II
Remifentanil (9739)II
Sufentanil (9740)II

The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company's primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to its company's customers.

Start Signature

Dated: August 21, 2015.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2015-21521 Filed 8-28-15; 8:45 am]

BILLING CODE 4410-09-P